Immutep Limited’s average one-year price target was raised to $7.40 per share from $0.98, a 652% increase versus the April 9, 2026 estimate. The update reflects sharply improved analyst expectations for the stock, though the article provides no operating or clinical catalysts. Market impact should be limited to sentiment around the name rather than the broader market.
Immutep Limited’s average one-year price target was raised to $7.40 per share from $0.98, a 652% increase versus the April 9, 2026 estimate. The update reflects sharply improved analyst expectations for the stock, though the article provides no operating or clinical catalysts. Market impact should be limited to sentiment around the name rather than the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
